Merck announced recentlythat its new HIV drug Pedro (doravirin tablets) has been officially approved
続きを読む 2020-12-08ニュース
Merck's new HIV drug Pedro (Doravirin) was approved in China
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
Pfizer announced that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Pr
続きを読む 2020-11-02
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shion
続きを読む 2020-10-18
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis
Gilead Sciences and Galapagos NV today announced that the European Commission (EC) has granted marke
続きを読む 2020-09-27
Janssen Announces European Commission Decision for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Comm
続きを読む 2020-09-09
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
Approval is based on results from SOLAR-1, where PIQRAY®in combination with fulvestrant nearly doubl
続きを読む 2020-08-20
Gastrointestinal stromal tumor (GIST) targeted new drugs! Avapritinib will be approved in the EU in September
Blueprint Medicines announced that the European Medicines Agency (EMA) Committee for Medicinal Produ
続きを読む 2020-07-29
Gilead's Veklury has been approved：Veklury is the First Approved Treatment Option for COVID-19 in the European Union
At present,The COVID-19 epidemic continues to spread rapidly around the world. As of 01am, July 04,
続きを読む 2020-07-05
Announcement on the extension of CPHI North America 2020 in September
Dear Customers,Unfortunately, we have to cancel the plan for our participation in the CPHI North Ame
続きを読む 2020-06-18
New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!
Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new
続きを読む 2020-06-16